Insider · CIK 0002007102
Robert Mashal
director
Files at NUVB (Nuvation Bio Inc.). First filing Apr 3, 2025, latest Apr 3, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
1 / 0
$167k bought, $0 sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NUVB: Nuvation Bio Inc.
NUVBOct 9, 2026 · close 5.00
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 62Notable | Nuvation Bio Inc. | $167k 100,000 shares | +100% | 0% from low-46% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 11, 2025 | NUVB Nuvation Bio Inc. | GGift Stock Option (Right to Buy)derivative | -350,001 | $0.00 | $0 | 391,178 | Aug 13, 2025 |
| Aug 11, 2025 | NUVB Nuvation Bio Inc. | GGift Stock Option (Right to buy)derivativeindirect: By Trust | +350,001 | $0.00 | $0 | 350,001 | Aug 13, 2025 |
| May 21, 2025 | NUVB Nuvation Bio Inc. | AGrant or award Stock Option (Right to Buy)derivative | +292,983 | $0.00 | $0 | 292,983 | May 23, 2025 |
| Apr 1, 2025 | NUVB Nuvation Bio Inc. | POpen-market purchase Class A Common Stockindirect: By Trust | +1,100 | $1.67 | $1,832 | 101,100 | Apr 3, 2025 |
| Apr 1, 2025 | NUVB Nuvation Bio Inc. | POpen-market purchase Class A Common Stockindirect: By Trust | +98,900 | $1.67 | $165k | 200,000 | Apr 3, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.